Skip to main content

XBI

ETF

XBI

ETF
Health Care
Biotechnology

Performance overview

XBI Price
Price Chart

Forward-looking statistics

Beta
1.06
Risk
24.56%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

An ETF providing exposure to a broad range of biotechnology companies.

Fund info

An ETF providing exposure to a broad range of biotechnology companies.

Investing methodPassively Managed
DiversifiedNo
Expense ratio0.35%
Asset classEquities

Company info

SectorHealth Care
IndustryBiotechnology
Website—
AUM$5.0B

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$0.01
Revenue per share—
Avg trading volume (30 day)$888M
Avg trading volume (10 day)$812M
Put-call ratioN/A

Macro factor sensitivity

Growth+0.7
Credit+5.1
Liquidity+0.3
Inflation-2.7
Commodities-0.3
Interest Rates-1.6

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayMarch 24, 2025

News

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research (July 10, 2025)
It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

CNBC Television (July 7, 2025)
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

CNBC Television (June 23, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free